Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Bio-X Center Establish Translational Medicine Lab in Shanghai

NEW YORK (GenomeWeb News) – Qiagen today announced it and the Bio-X Center of Shanghai Jiao Tong University will jointly create a translational medicine laboratory in Shanghai.

The lab, which is the first of its kind between Qiagen and a major research institution in China, will be outfitted with Qiagen's Pyromark Q24MDx pyrosequencing instrument and QIAcube instruments, as well as related products. Bio-X Center will use the products in various research projects including biomarker validation and analysis.

"Through this agreement with the Bio-X Center we can leverage our leading positions as a solutions provider in biological research, drug discovery, and personalized healthcare to help develop better diagnostics and therapies for the Chinese people," Victor Shi, Asia Pacific president of Qiagen, said in a statement.

Though the deal is Qiagen's first in China creating a translational medicine lab, the company has forged other deals in Asia. In 2007, it opened a subsidiary in Hong Kong to be a hub for further expansion in the region. The same year, Qiagen formed a joint venture with Bio*One Capital in Singapore focused on developing molecular diagnostic assays.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.